KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Travere Therapeutics (TVTX) Common Equity (2016 - 2025)

Historic Common Equity for Travere Therapeutics (TVTX) over the last 15 years, with Q3 2025 value amounting to $73.6 million.

  • Travere Therapeutics' Common Equity rose 34155.78% to $73.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $73.6 million, marking a year-over-year increase of 34155.78%. This contributed to the annual value of $59.1 million for FY2024, which is 7058.06% down from last year.
  • As of Q3 2025, Travere Therapeutics' Common Equity stood at $73.6 million, which was up 34155.78% from $32.7 million recorded in Q2 2025.
  • In the past 5 years, Travere Therapeutics' Common Equity ranged from a high of $362.7 million in Q1 2021 and a low of -$30.5 million during Q3 2024
  • Moreover, its 5-year median value for Common Equity was $116.5 million (2023), whereas its average is $150.3 million.
  • In the last 5 years, Travere Therapeutics' Common Equity skyrocketed by 36862.38% in 2023 and then tumbled by 11088.55% in 2024.
  • Over the past 5 years, Travere Therapeutics' Common Equity (Quarter) stood at $302.1 million in 2021, then tumbled by 85.82% to $42.9 million in 2022, then surged by 368.62% to $200.8 million in 2023, then tumbled by 70.58% to $59.1 million in 2024, then rose by 24.52% to $73.6 million in 2025.
  • Its Common Equity stands at $73.6 million for Q3 2025, versus $32.7 million for Q2 2025 and $32.8 million for Q1 2025.